DK1418905T3 - Terapeutisk middel til depletering af en uönsket proteinpopulation fra plasma - Google Patents

Terapeutisk middel til depletering af en uönsket proteinpopulation fra plasma

Info

Publication number
DK1418905T3
DK1418905T3 DK02751356T DK02751356T DK1418905T3 DK 1418905 T3 DK1418905 T3 DK 1418905T3 DK 02751356 T DK02751356 T DK 02751356T DK 02751356 T DK02751356 T DK 02751356T DK 1418905 T3 DK1418905 T3 DK 1418905T3
Authority
DK
Denmark
Prior art keywords
depleting
therapeutic agent
plasma protein
protein population
unwanted plasma
Prior art date
Application number
DK02751356T
Other languages
English (en)
Inventor
Mark B Pepys
Original Assignee
Pentraxin Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0119370.5A external-priority patent/GB0119370D0/en
Application filed by Pentraxin Therapeutics Ltd filed Critical Pentraxin Therapeutics Ltd
Application granted granted Critical
Publication of DK1418905T3 publication Critical patent/DK1418905T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
DK02751356T 2001-08-08 2002-07-29 Terapeutisk middel til depletering af en uönsket proteinpopulation fra plasma DK1418905T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0119370.5A GB0119370D0 (en) 2001-08-08 2001-08-08 Therapeutic agent
US09/985,699 US7045499B2 (en) 2001-08-08 2001-11-05 Therapeutic agent
PCT/GB2002/003504 WO2003013508A1 (en) 2001-08-08 2002-07-29 Therapeutic agent for depletion of an unwanted protein population from plasma

Publications (1)

Publication Number Publication Date
DK1418905T3 true DK1418905T3 (da) 2007-09-10

Family

ID=26246416

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02751356T DK1418905T3 (da) 2001-08-08 2002-07-29 Terapeutisk middel til depletering af en uönsket proteinpopulation fra plasma

Country Status (8)

Country Link
US (2) US7691897B2 (da)
EP (1) EP1418905B1 (da)
JP (1) JP4472333B2 (da)
AT (1) ATE361068T1 (da)
DE (1) DE60219926T2 (da)
DK (1) DK1418905T3 (da)
ES (1) ES2284895T3 (da)
WO (1) WO2003013508A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7390795B2 (en) 2000-12-18 2008-06-24 Pentraxin Therapeutics Limited Treatment and prevention of tissue damage
ATE361068T1 (de) 2001-08-08 2007-05-15 Pentraxin Therapeutics Ltd Wirkstoff zur entfernung einer unerwünschten proteinpopulation aus dem plasma
GB0211136D0 (en) 2002-05-15 2002-06-26 Univ London Treatment and prevention of tissue damage
GB0313386D0 (en) 2003-06-10 2003-07-16 Univ London Treatment of disease
EP2139524A1 (en) * 2007-03-23 2010-01-06 The Governors of the University of Alberta Multivalent heterobifunctional polymers and methods of their use
GB0718718D0 (en) * 2007-09-25 2007-11-07 Pentraxin Therapeutics Ltd Compound and use thereof
US9886546B2 (en) 2012-11-20 2018-02-06 General Electric Company Methods and apparatus to label radiology images
JP6964298B2 (ja) * 2016-06-29 2021-11-10 ザ スクリプス リサーチ インスティテュート ジプロボシム：新規かつ強力なクラスのｔｌｒアゴニスト
BR112021001992A2 (pt) * 2018-08-02 2021-05-04 The Board Of Regents Of The University Of Texas System efeito adjuvante do agonista tlr1/2 diprovocim sinergiza com anticorpos inibidores de checkpoint para eliminar doença
GB202014589D0 (en) 2020-09-16 2020-10-28 Ucl Business Ltd Agents for use in the treatment of amyloidosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62277352A (ja) * 1986-01-30 1987-12-02 Ono Pharmaceut Co Ltd 新規な６−ケト−プロスタグランジンｅ１誘導体、それらの製造方法およびそれらを有効成分として含有する細胞障害治療剤
US4895872A (en) * 1989-03-15 1990-01-23 Cetus Corporation Immunosupressive analogues and derivatives of succinylacetone
JPH0667472B2 (ja) * 1988-11-28 1994-08-31 鐘淵化学工業株式会社 血清アミロイドｐ蛋白用吸着体
WO1994022437A2 (en) * 1993-03-29 1994-10-13 Queen's University At Kingston Method for treating amyloidosis
GB9317120D0 (en) * 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
US6172045B1 (en) * 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
PL336589A1 (en) 1997-05-02 2000-07-03 Akzo Nobel Nv Serinic protease inhibitors
US6365570B1 (en) * 1997-10-10 2002-04-02 Universiteit Utrecht Pharmaceutical and diagnostic use of Serum Amyloid P component
ES2182203T3 (es) * 1997-10-31 2003-03-01 Hoffmann La Roche Derivados de d-prolina.
GB0119370D0 (en) * 2001-08-08 2001-10-03 Univ London Therapeutic agent
ATE361068T1 (de) 2001-08-08 2007-05-15 Pentraxin Therapeutics Ltd Wirkstoff zur entfernung einer unerwünschten proteinpopulation aus dem plasma
GB0313386D0 (en) * 2003-06-10 2003-07-16 Univ London Treatment of disease

Also Published As

Publication number Publication date
US7691897B2 (en) 2010-04-06
US8173694B2 (en) 2012-05-08
ATE361068T1 (de) 2007-05-15
US20100173969A1 (en) 2010-07-08
ES2284895T3 (es) 2007-11-16
DE60219926D1 (de) 2007-06-14
EP1418905A1 (en) 2004-05-19
JP4472333B2 (ja) 2010-06-02
US20060122124A1 (en) 2006-06-08
EP1418905B1 (en) 2007-05-02
JP2005501071A (ja) 2005-01-13
WO2003013508A1 (en) 2003-02-20
DE60219926T2 (de) 2007-11-22

Similar Documents

Publication Publication Date Title
PL371736A1 (en) Method for administering glp-1 molecules
DK1487493T3 (da) Konjugater af cytotoksiske midler og biologisk aktive peptider
CY1104988T1 (el) Μεθοδος αντιμετωπισης μολυνσεων του μεσου ωτος
EA200500218A1 (ru) ЛЕЧЕНИЕ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ С ПРИМЕНЕНИЕМ ИНТЕРФЕРОНА-β
DK1740197T3 (da) Prolyl-endopeptidease (PEP) og glutamin-endoprotease til behandlingen af cøliaki
CY1111613T1 (el) Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv
EP1381280A4 (en) VIRUS VECTORS AND THEIR USE IN THERAPEUTIC METHODS
BRPI0407583A (pt) solução oftálmica lìmpida e estável
DK1503788T3 (da) Behandling af alpha-galactosidase A-deficiens
DE60239931D1 (de) Kombinationstherapie
NO20053817D0 (no) Preparater og fremgangsmater for antiviral kombinasjonsterapi.
NO20050427L (no) Carvedilolfosfatsalter og/eller solvater derav, tilsvarende preparater og/eller behandlingsfremgangsmater
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
ATE481104T1 (de) Mittel zur behandlung von flaviviridae- infektionen
FR2845917B1 (fr) Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
DK1381382T3 (da) Fremgangsmåder og præparater til behandling af öjensygdomme
NO20033506L (no) Parasitticidale preparater og metoder for anvendelse
CL2004000261A1 (es) Procedimiento para la eliminacion de virus en soluciones de fibrinogeno de aplicacion terapeutica.
DE60219926D1 (de) Wirkstoff zur entfernung einer unerwünschten proteinpopulation aus dem plasma
DK1353948T3 (da) Oplöselige biologiske analoge til bata-amyloidpeptid
DE60204224D1 (de) Verwendung bestimmter substituierter pyrrolidone wie z.b. piracetam bei der behandlung von viralen und anderen erkrankungen
DK1169058T3 (da) Insulinlignende vækstfaktorbindingsprotein-4-protease
IS7798A (is) Efnasambönd, lyfjablöndur og aðferðir
DK1575531T3 (da) Terapier for kronisk inflammatorisk demyeliniserende polyneuropati under anvendelse af interferon-beta